221 related articles for article (PubMed ID: 32496716)
1. [Adamantan derivatives capable of inhibiting the reproduction of a Rimantadine resistant strain of influenza A(H1N1)pdm09 virus (Influenza A virus, Alphainfluenzavirus, Orthomyxoviridae).].
Garaev TM; Odnovorov AI; Kirillova ES; Burtseva EI; Finogenova MP; Mukasheva EA; Grebennikova TV
Vopr Virusol; 2020; 65(1):16-20. PubMed ID: 32496716
[TBL] [Abstract][Full Text] [Related]
2. [New adamantane derivatives and ways of overcoming the resistance of influenza A viruses to rimantadine and amantadine].
Shibnev VA; Garayev TM; Finogenova MP; Shevchenko ES; Burtseva EI
Vopr Virusol; 2011; 56(2):36-9. PubMed ID: 21545040
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of the antiviral activity of 2HCl*H-His-Rim compound compared to the anti-influenza drug Arbidol for influenza caused by A/duck/Novosibirsk/56/05 (H5N1) (Influenza A virus, Alphainfluenzavirus, Orthomyxoviridae).].
Deryabin PG; Garaev TM; Finogenova MP; Odnovorov AI
Vopr Virusol; 2019; 64(6):268-273. PubMed ID: 32168440
[TBL] [Abstract][Full Text] [Related]
4. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
5. Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
Kolocouris A; Tzitzoglaki C; Johnson FB; Zell R; Wright AK; Cross TA; Tietjen I; Fedida D; Busath DD
J Med Chem; 2014 Jun; 57(11):4629-39. PubMed ID: 24793875
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective synthesis of novel adamantane derivatives with high potency against rimantadine-resistant influenza A virus strains.
Kuznetsov NY; Tikhov RM; Godovikov IA; Medvedev MG; Lyssenko KA; Burtseva EI; Kirillova ES; Bubnov YN
Org Biomol Chem; 2017 Apr; 15(15):3152-3157. PubMed ID: 28338150
[TBL] [Abstract][Full Text] [Related]
7. [Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models].
Leneva IA; Fediakina IT; Eropkin MIu; Gudova NV; Romanovskaia AA; Danilenko DM; Vinogradova SM; Lepeshkin AIu; Shestopalov AM
Vopr Virusol; 2010; 55(3):19-27. PubMed ID: 20608077
[TBL] [Abstract][Full Text] [Related]
8. Designing inhibitors of M2 proton channel against H1N1 swine influenza virus.
Du QS; Huang RB; Wang SQ; Chou KC
PLoS One; 2010 Feb; 5(2):e9388. PubMed ID: 20186344
[TBL] [Abstract][Full Text] [Related]
9. [The antiviral activity of the adamantane derivatives against the influenza virus A (H1N1) pdm2009 model in vivo].
Shchelkanov MIu; Shibnev VA; Finogenova IT; Fediakina TM; Garaev TM; Markova NV; Kirillov IM
Vopr Virusol; 2014; 59(2):37-40. PubMed ID: 25069284
[TBL] [Abstract][Full Text] [Related]
10.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
Ma C; Zhang J; Wang J
Mol Pharmacol; 2016 Sep; 90(3):188-98. PubMed ID: 27385729
[TBL] [Abstract][Full Text] [Related]
12. New adamantane derivatives can overcome resistance of influenza A(H1N1)pdm2009 and A(H3N2) viruses to remantadine.
Shibnev VA; Garaev TM; Finogenova MP; Shevchenko ES; Burtseva EI
Bull Exp Biol Med; 2012 Jun; 153(2):233-5. PubMed ID: 22816091
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of amantadine-resistant influenza A (H1N1 pdm09) virus isolated from slum dwellers of Dhaka, Bangladesh.
Rahman M; Hoque SA; Islam MA; Rahman SR
Virus Genes; 2017 Jun; 53(3):377-385. PubMed ID: 28401407
[TBL] [Abstract][Full Text] [Related]
14. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance.
Belshe RB; Burk B; Newman F; Cerruti RL; Sim IS
J Infect Dis; 1989 Mar; 159(3):430-5. PubMed ID: 2915166
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of susceptibility of influenza viruses A (H1N1), the cause of infection in humans in April-May 2009, to antivirals in MDCK cell culture].
Romanovskaia AA; Durymanov AM; Sharshov KA; Zaĭkovskaia AV; Susloparov IM; Shestopalov AM; Leneva IA; Drozdov IG
Antibiot Khimioter; 2009; 54(5-6):41-7. PubMed ID: 20052917
[TBL] [Abstract][Full Text] [Related]
16. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.
Bright RA; Shay DK; Shu B; Cox NJ; Klimov AI
JAMA; 2006 Feb; 295(8):891-4. PubMed ID: 16456087
[TBL] [Abstract][Full Text] [Related]
17. Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.
Scott C; Kankanala J; Foster TL; Goldhill DH; Bao P; Simmons K; Pingen M; Bentham M; Atkins E; Loundras E; Elderfield R; Claridge JK; Thompson J; Stilwell PR; Tathineni R; McKimmie CS; Targett-Adams P; Schnell JR; Cook GP; Evans S; Barclay WS; Foster R; Griffin S
PLoS Pathog; 2020 Aug; 16(8):e1008716. PubMed ID: 32780760
[TBL] [Abstract][Full Text] [Related]
18. [Antiviral effect of «Kagocel» substance in vitro on influenza viruses H1N1, H1N1pdm09 and H3N2.].
Fediakina IT; Konopleva MV; Proshina ES; Linnik EV; Nikitina NI
Vopr Virusol; 2019; 64(3):125-131. PubMed ID: 31622059
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
20. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
